UNLABELLED: The purpose of this study was to develop a method of registering (18)F-FDG PET with MR permeability images for investigating the correlation of (18)F-FDG uptake, permeability, and cerebral blood volume (CBV) in children with pediatric brain tumors and their relationship with outcome. METHODS: Twenty-four children with brain tumors in a phase II study of bevacizumab and irinotecan underwent brain MR and (18)F-FDG PET within 2 wk. Tumor types included supratentorial high-grade astrocytoma (n = 7), low-grade glioma (n = 9), brain stem glioma (n = 4), medulloblastoma (n = 2), and ependymoma (n = 2). There were 33 cases (pretreatment only [n = 12], posttreatment only [n = 3], and both pretreatment [n = 9] and posttreatment [n = 9]). (18)F-FDG PET images were registered to MR images from the last time point of the T1 perfusion time series using mutual information. Three-dimensional regions of interest (ROIs) drawn on permeability images were automatically transferred to registered PET images. The quality of ROI registration was graded (1, excellent; 2, very good; 3, good; 4, fair; and 5, poor) by 3 independent experts. Spearman rank correlations were used to assess correlation of maximum tumor permeability (Kps(max)), maximum CBV (CBV(max)), and maximum (18)F-FDG uptake normalized to white matter (T/W(max)). Cox proportional hazards models were used to investigate associations of these parameters with progression-free survival (PFS). RESULTS: The quality of ROI registration between PET and MR was good to excellent in 31 of 33 cases. There was no correlation of baseline Kps(max) with CBV(max) (Spearman rank correlation = 0.018 [P = 0.94]) or T/W(max) (Spearman rank correlation = 0.07 [P = 0.76]). Baseline CBV(max) was correlated with T/W(max) (Spearman rank correlation = 0.47 [P = 0.036]). Baseline Kps(max), CBV(max), and T/W(max) were not significantly associated with PFS (P = 0.42, hazard ratio [HR] = 0.97, 95% confidence interval [CI] = 0.90-1.045, and number of events [n(events)] = 15 for Kps(max); P = 0.41, HR = 0.989, 95% CI = 0.963-1.015, and n(events) = 14 for CBV(max); and P = 0.17, HR = 1.49, 95% CI = 0.856-2.378, and n(events) = 15 for T/W(max)). CONCLUSION: (18)F-FDG PET and MR permeability images were successfully registered and compared across a spectrum of pediatric brain tumors. The lack of correlation between metabolism and permeability may be expected because these parameters characterize different molecular processes. The correlation of CBV and tumor metabolism may be related to an association with tumor grade. More patients are needed for a covariate analysis of these parameters and PFS by tumor histology.
UNLABELLED: The purpose of this study was to develop a method of registering (18)F-FDG PET with MR permeability images for investigating the correlation of (18)F-FDG uptake, permeability, and cerebral blood volume (CBV) in children with pediatric brain tumors and their relationship with outcome. METHODS: Twenty-four children with brain tumors in a phase II study of bevacizumab and irinotecan underwent brain MR and (18)F-FDG PET within 2 wk. Tumor types included supratentorial high-grade astrocytoma (n = 7), low-grade glioma (n = 9), brain stem glioma (n = 4), medulloblastoma (n = 2), and ependymoma (n = 2). There were 33 cases (pretreatment only [n = 12], posttreatment only [n = 3], and both pretreatment [n = 9] and posttreatment [n = 9]). (18)F-FDG PET images were registered to MR images from the last time point of the T1 perfusion time series using mutual information. Three-dimensional regions of interest (ROIs) drawn on permeability images were automatically transferred to registered PET images. The quality of ROI registration was graded (1, excellent; 2, very good; 3, good; 4, fair; and 5, poor) by 3 independent experts. Spearman rank correlations were used to assess correlation of maximum tumor permeability (Kps(max)), maximum CBV (CBV(max)), and maximum (18)F-FDG uptake normalized to white matter (T/W(max)). Cox proportional hazards models were used to investigate associations of these parameters with progression-free survival (PFS). RESULTS: The quality of ROI registration between PET and MR was good to excellent in 31 of 33 cases. There was no correlation of baseline Kps(max) with CBV(max) (Spearman rank correlation = 0.018 [P = 0.94]) or T/W(max) (Spearman rank correlation = 0.07 [P = 0.76]). Baseline CBV(max) was correlated with T/W(max) (Spearman rank correlation = 0.47 [P = 0.036]). Baseline Kps(max), CBV(max), and T/W(max) were not significantly associated with PFS (P = 0.42, hazard ratio [HR] = 0.97, 95% confidence interval [CI] = 0.90-1.045, and number of events [n(events)] = 15 for Kps(max); P = 0.41, HR = 0.989, 95% CI = 0.963-1.015, and n(events) = 14 for CBV(max); and P = 0.17, HR = 1.49, 95% CI = 0.856-2.378, and n(events) = 15 for T/W(max)). CONCLUSION: (18)F-FDG PET and MR permeability images were successfully registered and compared across a spectrum of pediatric brain tumors. The lack of correlation between metabolism and permeability may be expected because these parameters characterize different molecular processes. The correlation of CBV and tumor metabolism may be related to an association with tumor grade. More patients are needed for a covariate analysis of these parameters and PFS by tumor histology.
Authors: Frederic H Fahey; Paul E Kinahan; Robert K Doot; Mehmet Kocak; Harold Thurston; Tina Young Poussaint Journal: Med Phys Date: 2010-07 Impact factor: 4.071
Authors: Katherine A Zukotynski; Frederic H Fahey; Mehmet Kocak; Abass Alavi; Terence Z Wong; S Ted Treves; Barry L Shulkin; Daphne A Haas-Kogan; Jeffrey R Geyer; Sridhar Vajapeyam; James M Boyett; Larry E Kun; Tina Young Poussaint Journal: J Nucl Med Date: 2011-01-13 Impact factor: 10.057
Authors: Robert V Mulkern; Peter Forbes; Kevin Dewey; Stravoula Osganian; Maureen Clark; Sharon Wong; Uma Ramamurthy; Larry Kun; Tina Young Poussaint Journal: Acad Radiol Date: 2008-09 Impact factor: 3.173
Authors: Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson Journal: AJNR Am J Neuroradiol Date: 2004-05 Impact factor: 3.825
Authors: G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf Journal: Neurology Date: 1982-12 Impact factor: 9.910
Authors: Gethin Williams; Frederic H Fahey; S Ted Treves; Mehmet Kocak; Ian F Pollack; James M Boyett; Larry E Kun; Tina Young Poussaint Journal: Eur J Nucl Med Mol Imaging Date: 2008-04-19 Impact factor: 9.236
Authors: Michael C Kruer; Allen M Kaplan; Michael M Etzl; David F Carpentieri; Paul S Dickman; Kewei Chen; Kathleen Mathieson; Alison Irving Journal: J Neurooncol Date: 2009-06-09 Impact factor: 4.130
Authors: Sang Hyun Choi; Seung Chai Jung; Kyung Won Kim; Ja Youn Lee; Yoonseok Choi; Seong Ho Park; Ho Sung Kim Journal: J Neurooncol Date: 2016-04-23 Impact factor: 4.130
Authors: Mark W Kieran; Susan Chi; Stewart Goldman; Arzu Onar-Thomas; Tina Young Poussaint; Sridhar Vajapeyam; Frederic Fahey; Shengjie Wu; David C Turner; Clinton F Stewart; Marsha Moses; Roger J Packer; Regina Jakacki; Anu Banerjee; James M Boyett; Maryam Fouladi; Larry Kun Journal: Childs Nerv Syst Date: 2015-07-19 Impact factor: 1.475
Authors: Katherine Zukotynski; Frederic Fahey; Mehmet Kocak; Larry Kun; James Boyett; Maryam Fouladi; Sridhar Vajapeyam; Ted Treves; Tina Y Poussaint Journal: J Nucl Med Date: 2014-07-28 Impact factor: 10.057